Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove.

ABSTRACT: Targeted biologic therapies can elicit an undesirable host immune response characterized by the development of antidrug antibodies (ADA), an important cause of treatment failure. The most widely used biologic across immune-mediated diseases is adalimumab, a tumor necrosis factor inhibitor. This study aimed to identify genetic variants that contribute to the development of ADA against adalimumab, thereby influencing treatment failure. In patients with psoriasis on their first course of adalimumab, in whom serum ADA had been evaluated 6-36 months after starting treatment, we observed a genome-wide association with ADA against adalimumab within the major histocompatibility complex (MHC). The association signal mapped to the presence of tryptophan at position 9 and lysine at position 71 of the

SUBMITTER: Tsakok T 

PROVIDER: S-EPMC9977494 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature